학술논문
The glycine transporter 1 gene (GLYT1) is associated with methamphetamine‐use disorderPlease cite this article as follows: Morita Y, Ujike H, Tanaka Y, Kishimoto M, Okahisa Y, Kotaka T, Harano M, Inada T, Komiyama T, Hori T, Yamada M, Sekine Y, Iwata N, Iyo M, Sora I, Ozaki N, Kuroda S. 2007. The Glycine Transporter 1 Gene (GLYT1) is Associated With Methamphetamine‐Use Disorder. Am J Med Genet Part B 147B:54–58.
Document Type
Article
Author
Source
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics: The Official Publication of the International Society of Psychiatric Genetics; January 2008, Vol. 147 Issue: 1 p54-58, 5p
Subject
Language
ISSN
15524841; 1552485X
Abstract
Glycine transporter (GlyT)‐1 plays a pivotal role in maintaining the glycine level at the glutamatergic synapse. Glycine is an allosteric agonist of N‐methyl‐D‐aspartate (NMDA) receptors. Because activation of NMDA receptors is an essential step for induction of methamphetamine dependence and psychosis, differences in the functioning of GlyT‐1 due to genetic variants of the GlyT‐1 gene (GLYT1) may influence susceptibility. A case‐control genetic association study of the GLYT1 gene examined 204 patients with methamphetamine‐use disorder and 210 healthy controls. We examined three single nucleotide polymorphisms (SNPs), SNP1, IVS3 + 411C > T, rs2486001; SNP2, 1056G > A, rs2248829; and SNP3, IVS11 + 22G > A, rs2248632, of the GLYT1 gene and found that SNP1 showed a significant association in both genotype (P = 0.0086) and allele (P = 0.0019) with methamphetamine‐use disorder. The T‐G haplotype at SNP1 and SNP2 was a significant risk factor for the disorder (P = 0.000039, odds ratio: 2.04). The present findings indicate that genetic variation of the GLYT1 gene may contribute to individual vulnerability to methamphetamine dependence and psychosis. © 2007 Wiley‐Liss, Inc.